OrbiMed Advisors led the completion of a $200 million debt facility for Harmony Biosciences, a firm that develops treatment options for people living with rare diseases.
The financing is slated to support the company’s commercialization of the narcolepsy treatment WAKIX (pitosilant) in the U.S. The U.S. Food and Drug Administration approved the product in August 2019, but Harmony is in the process of executing its commercial launch.
Harmony was launched in 2017 with an emphasis on treating rare and orphan diseases related to the central nervous system disorders.
As for . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.